ARD-101

About Aardvark Therapeutics

Aardvark Therapeutics is a clinical-stage biotech focused on developing first-in-class, oral small-molecule therapies that inhibit hunger by targeting gut-brain signaling pathways. Its core achievement is the development of ARD-101, a compound designed to activate gut bitter taste receptors (TAS2Rs) to trigger local satiety hormone release, thereby suppressing hunger with minimal systemic exposure. The company's strategy involves initially targeting rare diseases with severe hyperphagia, such as Prader-Willi Syndrome and hypothalamic obesity, to establish proof-of-concept before expanding into the broader obesity market. Recent appointments of high-profile industry veterans to its board underscore its transition into late-stage clinical development.

About Aardvark Therapeutics

Aardvark Therapeutics is a clinical-stage biotech focused on developing first-in-class, oral small-molecule therapies that inhibit hunger by targeting gut-brain signaling pathways. Its core achievement is the development of ARD-101, a compound designed to activate gut bitter taste receptors (TAS2Rs) to trigger local satiety hormone release, thereby suppressing hunger with minimal systemic exposure. The company's strategy involves initially targeting rare diseases with severe hyperphagia, such as Prader-Willi Syndrome and hypothalamic obesity, to establish proof-of-concept before expanding into the broader obesity market. Recent appointments of high-profile industry veterans to its board underscore its transition into late-stage clinical development.

About Aardvark Therapeutics

Aardvark Therapeutics is a clinical-stage biotech focused on developing first-in-class, oral small-molecule therapies that inhibit hunger by targeting gut-brain signaling pathways. Its core achievement is the development of ARD-101, a compound designed to activate gut bitter taste receptors (TAS2Rs) to trigger local satiety hormone release, thereby suppressing hunger with minimal systemic exposure. The company's strategy involves initially targeting rare diseases with severe hyperphagia, such as Prader-Willi Syndrome and hypothalamic obesity, to establish proof-of-concept before expanding into the broader obesity market. Recent appointments of high-profile industry veterans to its board underscore its transition into late-stage clinical development.

Therapeutic Areas